Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. November 2025 18:14 ET | Quelle: Monteverde & Associates PC

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), who has...
14. November 2025 17:30 ET | Quelle: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
08. August 2019 16:07 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
07. August 2019 07:30 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
29. Juli 2019 07:00 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
09. Mai 2019 16:13 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
03. April 2019 16:04 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
28. Februar 2019 16:24 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
08. November 2018 17:23 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results

SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
24. September 2018 16:05 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present at Two Upcoming Investor Conferences

SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...

Nächste Seite